Screener
BioCryst Pharmaceuticals BCRX Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.
The source filing: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:03 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-012240
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Withholding taxes paid on stock-based awards | (8,847) | (7,535) | (2,172) |
| Common stock issued to directors in lieu of cash retainer | 59 | 34 | 342 |
| Net proceeds from term loans | — | — | 300,000 |
| Repayment of principal on term loans | (300,000) | — | (240,452) |
| Prepayment premium and fees on term loans | (9,886) | — | (21,261) |
| Payment of debt issuance costs on Pharmakon Tranche A term loan | — | — | (11,147) |
| Principal payments on royalty financing obligations | (22,883) | — | — |
| Payment of royalty release fees | (15,500) | — | — |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is BioCryst Pharmaceuticals's debt repayments?
- BioCryst Pharmaceuticals (BCRX) reported debt repayments of $184.15M in Q4 2025.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about BioCryst Pharmaceuticals's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude